Shortages of some life-saving antibiotics are putting growing numbers of patients at risk and fueling the evolution of “superbugs” that do not respond to modern medicines, according to a new report.

Drugmakers’ response to the threat posed by “superbugs” remains patchy even after years of warnings, according to the first analysis of individual companies’ efforts to tackle the antibiotic resistance crisis.